Firpi RJ et al. |
Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15113371
|
Hisanaga Y et al. |
Implication of nitric oxide synthase activity in the genesis of water immersion stress-induced gastric lesions in rats: the protective effects of FK506. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971291
|
Trotter JF et al. |
Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963078
|
Nakase H et al. |
Tacrolimus suppresses IL-12/IL23 p40 in Crohn's disease and heals fistulae refractory to anti-TNF-α therapy. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21434949
|
Nakase H et al. |
Tacrolimus: rescue therapy or experimental drug for severe ulcerative colitis? |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21198700
|
Hoshino H et al. |
Effects of FK506 on an experimental model of colitis in rats. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:7544633
|
Lawrance IC and Copeland TS |
Rectal tacrolimus in the treatment of resistant ulcerative proctitis. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18761706
|
Liberal R et al. |
Expert clinical management of autoimmune hepatitis in the real world. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28004405
|
Segal JP et al. |
Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28008631
|
Yamamoto T et al. |
Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27040167
|